×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INAB – in8bio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/9
08:58 am
inab
IN8bio promotes COO to president & COO [Seeking Alpha]
Low
Report
IN8bio promotes COO to president & COO [Seeking Alpha]
2/9
08:00 am
inab
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
Low
Report
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
2/3
08:00 am
inab
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
Low
Report
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
1/24
05:08 am
inab
IN8bio (NASDAQ:INAB) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
IN8bio (NASDAQ:INAB) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
1/17
06:56 am
inab
IN8bio (NASDAQ:INAB) was upgraded by analysts at Zacks Research to a "hold" rating.
Medium
Report
IN8bio (NASDAQ:INAB) was upgraded by analysts at Zacks Research to a "hold" rating.
1/12
08:55 am
inab
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma [Yahoo! Finance]
Medium
Report
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma [Yahoo! Finance]
1/12
08:00 am
inab
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
High
Report
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
12/19
08:35 am
inab
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager [Yahoo! Finance]
High
Report
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/9
08:31 am
inab
Form 8-K IN8BIO, INC. For: Feb 04
Low
Report
Form 8-K IN8BIO, INC. For: Feb 04
2/6
04:31 pm
inab
Form 4 IN8BIO, INC. For: Feb 04 Filed by: McCall Patrick
Medium
Report
Form 4 IN8BIO, INC. For: Feb 04 Filed by: McCall Patrick
2/6
04:31 pm
inab
Form 4 IN8BIO, INC. For: Feb 04 Filed by: Lamb Lawrence
Medium
Report
Form 4 IN8BIO, INC. For: Feb 04 Filed by: Lamb Lawrence
2/6
04:31 pm
inab
Form 4 IN8BIO, INC. For: Feb 04 Filed by: Rochlin Kate
Medium
Report
Form 4 IN8BIO, INC. For: Feb 04 Filed by: Rochlin Kate
2/6
04:31 pm
inab
Form 4 IN8BIO, INC. For: Feb 04 Filed by: Ho William Tai-Wei
Medium
Report
Form 4 IN8BIO, INC. For: Feb 04 Filed by: Ho William Tai-Wei
1/29
03:48 pm
inab
Form SCHEDULE 13G IN8BIO, INC. Filed by: FRANKLIN RESOURCES INC
Neutral
Report
Form SCHEDULE 13G IN8BIO, INC. Filed by: FRANKLIN RESOURCES INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: